Protein Therapeutics Market by Product, Application, and Geography - Forecast and Analysis 2023-2027

Protein Therapeutics Market Size 2023-2027

The protein therapeutics market size is estimated to grow by USD 153.56 billion at a CAGR of 9.14% between 2022 and 2027.  The market's growth relies on various factors, such as the rising demand for monoclonal antibodies (mAbs), the advancement of new therapies leveraging innovative technologies, and the presence of favorable reimbursement policies. These elements collectively contribute to the market's expansion, reflecting a shift towards more effective and targeted therapeutic approaches. As the demand for mAbs continues to rise, driven by their efficacy and specificity in treating various diseases, including cancer and autoimmune disorders, the market is expected to witness significant growth. Moreover, the development of novel therapies using cutting-edge technologies, such as genetic engineering and hybridoma technology, further fuels market expansion. Additionally, favorable reimbursement policies for mAb therapies provide a supportive environment for market growth, encouraging both research and patient access to these innovative treatments.

It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

This market report extensively covers market segmentation by product (mABs, human insulin, erythropoietin, clotting factors, and others), application (metabolic disorders, immunologic disorders, hematological disorders, cancer, and genetic disorders), and geography (North America, Europe, Asia, and Rest of World (ROW)).

By Product

The market share growth by the MAbs segment will be significant during the forecast period. The market for protein therapeutics is anticipated to expand as a result of rising cancer rates and the advantages of next-generation antibodies. Because of alterations in lifestyle, such as smoking, drinking, and sedentary employment, the burden of cancer is increasing. Due to this, sales of MAbs such as GAZYVA, BLINCYTO, Removab, and Poteligeo, four major next-generation antibodies used to treat cancer, have increased.

Get a glance at the market contribution of various segments View the PDF Sample

The MAbs segment was valued at USD 79.64 billion in 2017. ADCs are powerful cytotoxic drugs connected to mAbs. These medications have been demonstrated to be effective and potent in the treatment of various illnesses, including cancer and hematological malignancies. As a result, companies are showing interest in cutting-edge technologies like ImmunoGens IMGN, Immunomedics IMMU, and Seattle Genetics SGEN. Additionally, the increased use of ADCs in drug development boosts sales on the international market. The market is also driven by the introduction of immune checkpoint inhibitors. The first immune checkpoint inhibitor to receive regulatory approval for treating cancer was ipilimumab (YERVOY) in 2011. The only two anti-PD-1 therapies approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat melanoma are pembrolizumab (KEYTRUDA) and nivolumab (OPDIVO). Pembrolizumab, however, demonstrated efficacy in treating bladder cancer, urothelial cancer, head and neck cancer, gastric cancer, NHL, breast cancer, and lung cancer. They are also being studied for the treatment of multiple tumors. Hence, all such factors will fuel the market growth during the forecast period. 

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Due to increased demand for already-available protein therapeutics and the introduction of fresh ones, the market in North America is expanding quickly. For instance, Bristol-Myers Squibb introduced OPDIVO (nivolumab) for the treatment of advanced renal cell carcinoma and received approval from the US FDA for the treatment of HL. Novartis introduced Cosentyx to treat autoimmune and inflammatory diseases. Additionally, the market will grow as certain formulations receive accelerated approvals. This is because these designations will grant quick approvals for the products in the pipeline and market exclusivities for the medications that have already received approval. More companies will be inspired to engage in R&D activities and enter the market as a result. 

The rising incidence of cancer, autoimmune diseases, metabolic diseases, musculoskeletal disorders, central nervous system disorders, and blood disorders is the main factor driving the market in this area. In the US, an estimated 20,000 people have been diagnosed with hemophilia, and 75–85 percent of those people have hemophilia A. Additionally, according to research, 400 newborns in the US are affected by hemophilia every year. In addition, the anticipated launch of drugs such as brodalumab by AstraZeneca and Valeant Pharmaceuticals to treat autoimmune and inflammatory disorders will help in market growth during the forecast period. Furthermore, patient assistance programs offered by governmental and non-governmental organizations are anticipated to fuel the market growth during the forecast period. 

Market Dynamics and Customer Landscape

The market is witnessing significant growth, driven by rising cases of autoimmune disorders and cardiovascular diseases. Chemotherapy and other treatments utilize genetically engineered proteins and natural proteins to target specific molecules, enhancing protein's activity duration. These therapies are vital in treating immunological diseases and managing chronic disorders. The market is fueled by advancements in therapeutic protein drugs and Monoclonal antibodies segment. Developing economies are increasingly adopting these quality drugs for various metabolic disorders, showcasing the market's versatile therapies. As a result, the market is poised for further growth and innovation. The market within the healthcare industry is expanding, driven by innovations in recombinant proteins and monoclonal antibodies. These therapies are crucial in managing metabolic disorders and addressing various health issues, including sugars imbalance and the need for specialized medicine. Our researchers analyzed the data with 2022 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The availability of favorable reimbursement policies is notably driving market growth.  Although reimbursement of diagnostic tools and biological medicines is anticipated to drive the market during the forecast period, protein therapeutics are expensive and cannot be afforded by everyone. Plans like public reimbursement schemes lessen the cost of treatments. The status of drug reimbursement does indeed vary from region to region, with factors such as cost-effectiveness and other considerations often determining coverage. This variation affects major healthcare institutions and patients alike, impacting access to versatile therapies. In developing economies, where access to healthcare can be limited, reimbursement policies play a crucial role in determining the availability of medications, including those derived from natural proteins. However, the increasing demand for costly drugs is an important reason for these drugs to be included in reimbursement plans.

Medicare and Medicaid reimbursement plans are anticipated to have an impact on how diseases like diabetes, which have high prevalence and incidence rates in the US, are perceived globally. Medicare covers beneficiaries who are 65 years of age or older, have end-stage renal disease, and are younger than 65 but have certain disabilities. People with diabetes or those who are at risk for developing it are helped by the Medicare Part B plan. By providing reimbursement, insurance coverage ensures better disease control and motivates people to choose treatment. Such factors are expected to drive the growth of the global market during the forecast period.

Significant Market Trends

The increase in chronic diseases is an emerging trend in market growth. One of the leading causes of disabilities and fatalities across the world is chronic diseases. Type 2 diabetes, cancer, chronic obstructive pulmonary disease, and CVDs are the four main chronic diseases. These illnesses are caused by unhealthy diets, lack of exercise, tobacco use, high blood pressure, high cholesterol, and obesity.

Exercise, a better diet, as well as early detection and treatment therapy, for which protein therapeutics are necessary, can prevent and manage chronic diseases like heart disease, asthma, cancer, and diabetes, which are typically incurable illnesses or conditions. As a result, the use of cutting-edge therapies like protein therapeutics has increased along with the prevalence of chronic diseases. Hence, such factors are expected to drive the growth of the global market during the forecast period.

Major Market Challenge

The complicated regulatory framework is a major challenge impeding the market growth. Obtaining regulatory approval is frequently challenging, unpredictable, and arbitrary. Before being approved and put on the market, protein therapeutics must pass a variety of strict regulations. Globally speaking, the US is currently lagging behind other regulated markets, particularly the EU, in terms of the competition from biosimilar products. Despite the absence of new competitors, the US market for biosimilars continues to garner interest. The approval and regulatory framework in which biosimilar developers must operate is the first and most important factor that is anticipated to determine the future of the biosimilar market in the US. Many companies are making investments in it because it appears to be a lucrative market.

On the other hand, strict laws are upheld in Europe to protect people by ensuring their safety and effectiveness. The market has better traction in most European nations, though, where the approval process is a little bit faster than it is in the US. The majority of technical difficulties in every region are caused by the creation of new products that become apparent during the clinical trial stage. companies may incur costs, create uncertainty, or affect other trials if they fail to provide clinical data with encouraging results in a particular area. companies who are creating new protein therapeutics in the market may experience difficulties as a result. Hence, all these factors will fuel the market growth during the forecast period. 

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Amgen Inc. - The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics. The key offerings of the company include protein therapeutics such as Amgen fusion protein.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• AbbVie Inc.
• AstraZeneca Plc
• Biocon Ltd.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Celltrion Healthcare Co. Ltd.
• Creative Biolabs
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Intas Pharmaceuticals Ltd.
• Ipsen Pharma
• Johnson and Johnson Services Inc.
• LGM Pharma LLC
• Midas Pharma GmbH
• Novartis AG

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments

• Product Outlook 
  • MAbs
  • Human insulin
  • Erythropoietin
  • Clotting factors
  • Others

• Application Outlook 
  • Metabolic disorders
  • Immunologic disorders
  • Hematological disorders
  • Cancer
  • Genetic disorders

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
    • Others
  • Rest of World
    • Saudi Arabia
    • South Africa
    • Others

Market Analyst Overview

The market is driven by pharmaceutical firms, research centers, and skilled working professions focusing on innovative biological drugs. These therapies aim to improve patient outcomes while managing healthcare expenditure. The sector's growth is supported by robust healthcare infrastructure and advancements in biotechnology, including recombinant DNA technology, protein engineering, and cell culture techniques. Academic institutions, research organizations, and biotechnology companies play pivotal roles in developing protein-based drugs. Factors like chronic disease prevalence, an aging population, and the need for personalized medicines due to genetic conditions and medical history drive market expansion. Hospitals, research institutes, and technological advancements further contribute to the sector's progress.

However, challenges such as high cost, complex procedures, and rising investment are present. Diseases targeted by these therapies include rheumatoid arthritis, various cancers, systemic lupus erythematosus, multiple sclerosis, Crohn’s disease, psoriasis, and ulcerative colitis. Protein therapeutics also play a crucial role in transplantation, managing diabetic cases, regulating hormone levels, and controlling glucose and energy balance. Specific conditions like Gaucher's disease, hemochromatosis, and immunological disorders benefit from these treatments. They are also essential in supporting patients undergoing chemotherapy for cancer and managing AIDS. Companies like BioNtech, Autolus, and Lumosa Therapeutics are prominent in this field. Protein therapeutics are used in treating acute ischemic stroke, with products like PeproTech providing vital bioscience reagents.

Market Scope
Report Coverage	Details
Page number	180
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 9.14%
Market growth 2023-2027	USD 153.56 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	8.01
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., Creative Biolabs, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., Ipsen Pharma, Johnson and Johnson Services Inc., LGM Pharma LLC, Midas Pharma GmbH, Novartis AG, Novo Nordisk AS, Pfizer Inc., PV Pharma Healthcare Pvt. Ltd., and Sanofi SA
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period.
Customization purview	If market our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch